生物制剂治疗幼年特发性关节炎新策略

幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是儿童时期最常见的风湿性疾病之一,预后较差.生物制剂改变了JIA的传统治疗模式,使JIA患儿的病情明显改善.JIA是一种异质性疾病,采用生物制剂治疗前要评估其病情,根据其不同的临床表现选择相应的治疗方案.治疗过程中也要评估临床疗效及不良反应,平衡治疗的风险和益处.该文重点介绍生物制剂在JIA中的应用现状,并根据2011年美国风湿病学会发布的治疗JIA的循证建议对生物制剂的选择进行阐述.

New strategy of biological agents on juvenile idiopathic arthritis

Juvenile idiopathic arthritis(JIA) is the most common rheumatology disease in childhood period with poor prognosis.Biological agents changed the traditional mode of treatment for JIA and improved condition of children with JIA.JIA is a heterogeneous disease.So the condition of patient should be assessed before using biological agents to treat JIA.Different treatment options are evaluated according to different clinical manifestations.We should assess clinical efficacy and adverse reaction in the course of treatment and balance the risks and benefits of treatment.This article focuses on the application status of boilogical agents on JIA and explains selection of biological agents according to 2011 American College of Rheumatology recommendations for the treatment of JIA.